156 related articles for article (PubMed ID: 12838295)
61. Low-dose aspirin use and performance of immunochemical fecal occult blood tests.
Brenner H; Tao S; Haug U
JAMA; 2010 Dec; 304(22):2513-20. PubMed ID: 21139112
[TBL] [Abstract][Full Text] [Related]
62. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
[TBL] [Abstract][Full Text] [Related]
63. [A double immunochemical method for detecting faecal haemoglobin and albumin in rectal screening].
Tarpay A; Szabadosné Németh M; Orosz E; Kásler M; Burai M; Pap A; Ottó S
Magy Onkol; 2011 Nov; 55(4):268-73. PubMed ID: 22128309
[TBL] [Abstract][Full Text] [Related]
64. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
65. Effectiveness of repeated screening using the fecal occult blood test and its impact on reducing false-negative cancer cases.
Nishida H; Urano S
Eur J Cancer Prev; 2011 May; 20(3):184-9. PubMed ID: 21301345
[TBL] [Abstract][Full Text] [Related]
66. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
[TBL] [Abstract][Full Text] [Related]
67. Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies.
Castells A; Bessa X; Quintero E; Bujanda L; Cubiella J; Salas D; Lanas A; Carballo F; Morillas JD; Hernández C; Jover R; Montalvo I; Arenas J; Cosme A; Hernández V; Iglesias B; Castro I; Cid L; Sala T; Ponce M; Andrés M; Teruel G; Peris A; Roncales MP; González-Rubio F; Seoane-Urgorri A; Grau J; Serradesanferm A; Pellisé M; Ono A; Cruzado J; Pérez-Riquelme F; Alonso-Abreu I; Carrillo-Palau M; de la Vega-Prieto M; Iglesias R; Amador J; Blanco JM; Sastre R; Ferrándiz J; González-Hernández MJ; Andreu M;
J Natl Cancer Inst; 2013 Jun; 105(12):878-86. PubMed ID: 23708054
[TBL] [Abstract][Full Text] [Related]
68. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening.
Zhang B; Fattah A; Nakama H
Hepatogastroenterology; 2000; 47(32):414-8. PubMed ID: 10791202
[TBL] [Abstract][Full Text] [Related]
69. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
[TBL] [Abstract][Full Text] [Related]
70. Repeated faecal occult blood testing is associated with decreased advanced colorectal cancer risk: A population-based study.
James PD; Rabeneck L; Yun L; Paszat L; Baxter NN; Govindarajan A; Antonova L; Tinmouth JM
J Med Screen; 2018 Sep; 25(3):141-148. PubMed ID: 28862521
[TBL] [Abstract][Full Text] [Related]
71. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
72. Effect of faecal occult blood testing on colorectal cancer mortality in the surveillance of subjects at moderate risk of colorectal neoplasia: a case-control study.
Lamah M; Norris J; Caffarey SM; Broughton M; Marks CG
Int J Colorectal Dis; 2001 Sep; 16(5):313-7. PubMed ID: 11686530
[TBL] [Abstract][Full Text] [Related]
73. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
[TBL] [Abstract][Full Text] [Related]
74. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
Musil D; Tillich J
Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
[TBL] [Abstract][Full Text] [Related]
75. Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study.
Vicentini M; Zorzi M; Bovo E; Mancuso P; Zappa M; Manneschi G; Mangone L; Giorgi Rossi P;
Int J Cancer; 2019 Jul; 145(1):110-121. PubMed ID: 30585621
[TBL] [Abstract][Full Text] [Related]
76. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
[TBL] [Abstract][Full Text] [Related]
77. Relationships between a sign of rectal bleeding and the results of an immunochemical occult blood test, and colorectal cancer.
Nakama H; Zhang B; Abdul Fattah AS; Kamijo N; Fukazawa K
Eur J Cancer Prev; 2000 Oct; 9(5):325-8. PubMed ID: 11075885
[TBL] [Abstract][Full Text] [Related]
78. Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study.
Bertario L; Russo A; Crosignani P; Sala P; Spinelli P; Pizzetti P; Andreola S; Berrino F
Eur J Cancer; 1999 Jun; 35(6):973-7. PubMed ID: 10533481
[TBL] [Abstract][Full Text] [Related]
79. An evaluation of mass screening using fecal occult blood test for colorectal cancer in Japan: a case-control study.
Hiwatashi N; Morimoto T; Fukao A; Sato H; Sugahara N; Hisamichi S; Toyota T
Jpn J Cancer Res; 1993 Nov; 84(11):1110-2. PubMed ID: 8276715
[TBL] [Abstract][Full Text] [Related]
80. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
